FULC · Categories · Downgrades
FULC - Analyst downgrades
Fulcrum Therapeutics Inc. (FULC) analyst downgrades - real-time wire coverage filtered to Downgrades only.
Recent Downgrades for FULC
- Fulcrum Therapeutics downgraded by AnalystAnalyst downgraded Fulcrum Therapeutics from Overweight to Underweight
- Fulcrum Therapeutics downgraded by Piper Sandler with a new price targetPiper Sandler downgraded Fulcrum Therapeutics from Overweight to Neutral and set a new price target of $3.00
- Fulcrum Therapeutics downgraded by H.C. Wainwright with a new price targetH.C. Wainwright downgraded Fulcrum Therapeutics from Buy to Neutral and set a new price target of $3.00
- Fulcrum Therapeutics downgraded by Leerink Partners with a new price targetLeerink Partners downgraded Fulcrum Therapeutics from Outperform to Market Perform and set a new price target of $4.00
- Fulcrum Therapeutics downgraded by Truist with a new price targetTruist downgraded Fulcrum Therapeutics from Buy to Hold and set a new price target of $4.00
- Fulcrum Therapeutics downgraded by Stifel with a new price targetStifel downgraded Fulcrum Therapeutics from Buy to Hold and set a new price target of $3.00
- Fulcrum Therapeutics downgraded by H.C. Wainwright with a new price targetH.C. Wainwright downgraded Fulcrum Therapeutics from Buy to Neutral and set a new price target of $4.00 from $17.00 previously
- Fulcrum Therapeutics downgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts downgraded Fulcrum Therapeutics from Outperform to Sector Perform and set a new price target of $4.00 from $15.00 previously
- Fulcrum Therapeutics downgraded by Leerink Partners with a new price targetLeerink Partners downgraded Fulcrum Therapeutics from Outperform to Market Perform and set a new price target of $4.00
- Fulcrum Therapeutics downgraded by BofA Securities with a new price targetBofA Securities downgraded Fulcrum Therapeutics from Neutral to Underperform and set a new price target of $2.00 from $10.00 previously
- Fulcrum Therapeutics downgraded by StifelStifel downgraded Fulcrum Therapeutics from Buy to Hold
- Fulcrum Therapeutics downgraded by Cantor FitzgeraldCantor Fitzgerald downgraded Fulcrum Therapeutics from Overweight to Neutral
- Fulcrum Therapeutics downgraded by Goldman with a new price targetGoldman downgraded Fulcrum Therapeutics from Buy to Neutral and set a new price target of $3.00 from $9.00 previously
- Fulcrum Therapeutics downgraded by H.C. Wainwright with a new price targetH.C. Wainwright downgraded Fulcrum Therapeutics from Buy to Neutral and set a new price target of $6.00 from $20.00 previously
- Fulcrum Therapeutics downgraded by Credit Suisse with a new price targetCredit Suisse downgraded Fulcrum Therapeutics from Outperform to Neutral and set a new price target of $8.00 from $11.00 previously
- Fulcrum Therapeutics downgraded by Stifel with a new price targetStifel downgraded Fulcrum Therapeutics from Buy to Hold and set a new price target of $6.00 from $35.00 previously
- Fulcrum Therapeutics downgraded by Morgan Stanley with a new price targetMorgan Stanley downgraded Fulcrum Therapeutics from Overweight to Equal-Weight and set a new price target of $8.00 from $27.00 previously
- Fulcrum Therapeutics downgraded by BofA SecuritiesBofA Securities downgraded Fulcrum Therapeutics from Neutral to Underperform
Other FULC categories
Is something on this page wrong? Request a change